WO2006085441A1 - Adamts13活性検定用抗体及び活性検定方法 - Google Patents
Adamts13活性検定用抗体及び活性検定方法 Download PDFInfo
- Publication number
- WO2006085441A1 WO2006085441A1 PCT/JP2006/301231 JP2006301231W WO2006085441A1 WO 2006085441 A1 WO2006085441 A1 WO 2006085441A1 JP 2006301231 W JP2006301231 W JP 2006301231W WO 2006085441 A1 WO2006085441 A1 WO 2006085441A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- antibody
- seq
- sequence listing
- reactivity
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Definitions
- a von Willebrand factor hereinafter also referred to as “VWF” or a peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing is provided with a VWF cleavage enzyme (hereinafter also referred to as “ADAMTS13”). It has specific reactivity (binding) to the antigen-determining site generated when it is allowed to act, ADAMTS 13 acts, and it does not have significant specific reactivity with the VWF or the peptide
- the present invention relates to antibodies, particularly monoclonal antibodies, and methods for producing them, and their uses.
- Thrombotic thrombocytopenic purpura is a syndrome characterized by thrombocytopenia, hemolytic anemia, swaying neuropsychiatric disorder and the like. In the past, approximately 80% of patients had a poor prognosis that died within 3 months. Today, plasma replacement has greatly improved prognosis.
- ADAMTS13 VWF-cleaving enzyme
- ADAMTS 13 is a zinc-type meta-oral protease that specifically cleaves the Tyr842-Met843 bond of the VWF subunit.
- This enzyme activity is measured by VWF multimer analysis in which VWF fragments generated using VWF as a substrate are detected by electrophoresis.
- This method has the advantage that ADMATS13 activity can be accurately measured. Therefore, the development of a particularly simple measurement method has been desired.
- Non-patent documents 6 to 8 report a method for measuring ADAMTS13 activity using the A2 domain of VWF, which is a substrate of ADAMTS 13, or a part thereof. These are substrates expressed in E. coli by genetic recombination that is not natural. In the above measurement method, these substrates are decomposed by ADAMTS13 in the plasma sample, and the molecular weight of the substrate molecule is determined by electrophoresis Western plot, and the undegraded residue after the reaction between the substrate and the enzyme. ADAMTS13 activity is detected and measured by immunological measurement of the substrate. However, in these methods, the activity of ADAMTS 13 and the signal intensity obtained are inversely related and the so-called calibration curve has a negative slope. Reproducibility could not be obtained and it became a problem.
- Non-patent Document 9 a method for measuring plasma ADAMTS13 activity using a quenching fluorescent substrate has been reported (Non-patent Document 9). This method has a calibration curve showing a positive slope in which the fluorescence intensity increases with increasing ADAMTS13 activity.
- Non-patent Document 9 there is a problem in using it in a general clinical laboratory because it has to be rate-assessed using a fluorometer with a specially synthesized chemically expensive substrate.
- Non-Patent Document 1 New Engl. J. Med. 339, 1578-1584, 1998
- Non-Patent Document 2 New Engl. J. Med. 339, 1585-1594, 1988
- Non-Patent Document 3 J. Hematol. 74, 101-108, 2001
- Non-Patent Document 4 J Biochem. 130, 475-480, 2001
- Non-Patent Document 5 J. Biol. Chem. 276, 41059-41063, 2001
- Non-Patent Document 6 Blood, 103, 607-612, 2004
- Non-Patent Document 7 J. Thromb. Haemost. 2, 485-491, 2004
- Non-Patent Document 8 Thromb Haemost. 91, 806-811, 2004
- Non-Patent Document 9 Journal of the Japan Thrombosis and Hemostasis, 15, 421, 2004
- the present invention has the following constitutional power.
- VWF von Willebrand factor
- the antigen determination site generated when ADAM TS13 is allowed to act on VWF or a peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 in the sequence listing is generated when the VWF or the peptide is cleaved by ADAMTS13. 2.
- the antigen-determining site is present in the N-terminal peptide fragment or C-terminal peptide fragment newly generated at the cleavage site where VWF or the peptide was cleaved by ADAMTS 13; The antibody according to item 2.
- Reactivity against the peptide described in SEQ ID NO: 2 in the sequence listing At least three times greater than the reactivity against the peptide containing the sequence described in SEQ ID NO: 1 in the sequence listing Or the antibody of claim 1.
- Reactivity against the peptide described in SEQ ID NO: 2 in the sequence listing is at least 5 times greater than the reactivity against the peptide described in SEQ ID NO: 8 in the sequence listing, according to any one of items 1 to 8 above The antibody described.
- Reactivity against the peptide of SEQ ID NO: 10 in the sequence listing is at least 5 times greater than the reactivity against VWF purified from human plasma, as described in paragraphs 1 to 3 and 12 to 14 above.
- Reactivity against the peptide of SEQ ID NO: 10 in the Sequence Listing At least 3 times greater than the reactivity to the peptide of SEQ ID NO: 1 in the Sequence Listing, the preceding paragraphs 1 to 3 and 12 to 12 16.
- the reactivity in the peptide of SEQ ID NO: 10 in the sequence listing is at least 5 times greater than the reactivity to the peptide in SEQ ID NOs: 8 and 11 in the sequence listing;
- the antibody according to any one of items 1 to 11 above which is a monoclonal antibody produced by a hyperidoma whose deposit number is FERM BP-10480 or FERM BP-10479.
- a method for measuring ADAMTS 13 activity in a sample comprising the step of reacting at least one antibody according to any one of the above.
- a step of reacting VWF with a specimen to be assayed for ADAMTS 13 activity, and a reaction product of the step comprising at least one of the items described in any one of paragraphs 1 to 21 above A method for measuring ADAMTS 13 activity in a sample, comprising a step of reacting an antibody.
- the antibody of the present invention is an antibody that specifically recognizes an antigenic determinant site generated when ADAMTS 13 is allowed to act on VWF or a peptide having the amino acid sequence set forth in SEQ ID NO: 1 in the sequence listing.
- the antibody does not have a significant specific reactivity with the VWF or the peptide, in which ADAMTS 13 does not act.
- it is possible to measure and assay ADAMTS13 enzyme activity. That is, by using the antibody of the present invention, (1) rapid and simple measurement of ADAMTS13 activity by sandwich immunoassay, and (2) rapid and simple measurement of ADAMTS13 activity by particle-labeled immunoassay are possible. Therefore, the present invention is of great significance in (3) the development of therapeutic agents, diagnostic agents, etc. based on these results.
- the antibody of the present invention is stably produced by monocloned fused cells, and thus has high industrial utility value.
- FIG. 1 is a diagram showing a calibration curve of ADAMTS13 activity measurement using the monoclonal antibody of the present invention as a secondary antibody and the measurement results of USS examples. (Examples 7 and 8)
- FIG. 2 is a diagram showing a calibration curve for measuring ADAMTS13 activity using the monoclonal antibody of the present invention as a solid phase. (Example 9)
- the antibody refers to any of a monoclonal antibody and a polyclonal antibody.
- a monoclonal antibody is an antibody produced from a monocloned fused cell prepared by a known method.
- the antibody of the present invention includes whole antibody molecules or partial fractions of antibody molecules having antibody activity.
- the antigen used as an immunogen for producing the antibody of the present invention is not particularly limited as long as it can solve the problems of the present invention, but a peptide is preferably used. Includes those bound to a carrier protein.
- the “peptide” refers to a peptide in which two or more amino acids are bound by a peptide bond.
- ADAMTS13 is a zinc-type meta-oral protease that specifically cleaves the bond corresponding to the bond between the 1065th tyrosin (Tyrl605) and the 1606th methionine (Metl606) of the VWF molecule.
- Tyrl605 the 1065th tyrosin
- Metal606 the 1606th methionine
- a new C-terminal and N-terminal are generated on the amino acid sequence.
- new antigenic determinants can occur. If an antibody that recognizes the antigen-determining site is prepared, an antibody that can specifically bind to the cleaved VWF is expected.
- the antibody in the present invention is not particularly limited as long as it has specific reactivity at an antigen determination site generated in either a newly generated N-terminal peptide or C-terminal peptide.
- ADAMTS13 is reported to specifically cleave the binding of Tyrl605-Metl606 using peptides from the 1459th Asp to the 1668th Arg of the VWF molecule as substrates.
- VWF73 a peptide consisting of 73 amino acids from the 1596th Asp to the 1668th Arg
- N-10 peptide is a peptide consisting of the amino acid sequence represented by SEQ ID NO: 2 in the sequence listing.
- VWF von Willebrand factor
- ADAMTS13 a peptide containing the amino acid sequence set forth in SEQ ID NO: 1 in the sequence listing by using the N-10 peptide as an immunogen. It has a specific reactivity to the antigen-determining site that occurs in the blood and is affected by ADAMTS 13! / ⁇ ⁇ Significantly different from VWF or the peptide
- the antibody of the present invention having no specific reactivity could be obtained.
- VAM that is not affected by ADAMTS 13 and is not cleaved or includes the amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing is also referred to as “complete VWF molecule”.
- a peptide including the amino acid sequence shown in SEQ ID NO: 1 in the sequence table has an amino acid strength of 73 to 2050, preferably 73 to 210, as long as it can undergo hydrolysis of ADAMTS13.
- Preferred is a peptide (73 amino acids) consisting of the amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing.
- the antibody of the present invention obtained by force is an antibody that recognizes an antigenic determinant site generated when ADAMTS 13 is allowed to act on VWF or a peptide containing the amino acid sequence described in SEQ ID NO: 1 in the Sequence Listing. And a complete VWF molecule with no significant reactivity.
- An example of a strong antigen determination site is an antigen determination site that can be formed into an N-terminal peptide fragment (peptide of SEQ ID NO: 2) generated when the peptide of SEQ ID NO: 1 is hydrolyzed by ADAMTS.
- the N-terminal antigen-determining site requires the presence of tyrosine (Tyr) at the C-terminus.
- the peptide having one less N-terminal amino acid in SEQ ID NO: 2 has antigenicity, and the peptide having two fewer amino acids has no antigenicity. Therefore, the N-terminal antigen-determining site has at least 9 antigen-determining sites. It is presumed to be a bent structure with amino acid power.
- not having significant reactivity means that there is no significant binding to a complete VWF molecule, and therefore, when analyzed by a known immunochemical technique such as Western plot or ELISA, A signal that is only comparable to a signal in the background (a signal without an antibody or a signal obtained with an antibody unrelated to the analyte).
- the antibody of the present invention is prepared by (a) reacting each of the antibody with VWF purified from human plasma and the peptide described in SEQ ID NO: 2 in the sequence listing in which the antibody is immobilized on a microplate well.
- the property that the reactivity to the peptide shown in SEQ ID NO: 2 in the sequence table is at least 5 times greater than the reactivity to VWF purified from human plasma (b) the sequence sequence sequence in which the antibody is immobilized on a microplate well When reacted with the peptide of No. 2 and the peptide containing the sequence of SEQ ID No. 1 in the sequence listing, the reactivity to the peptide of SEQ ID No. 2 of the sequence listing is shown in SEQ ID No.
- the antibody of the present invention can be obtained by (d) reacting the antibody with the peptide shown in SEQ ID NO: 10 in the sequence listing immobilized on a microplate well and VWF purified from human plasma, respectively.
- the property that the reactivity to the peptide shown in SEQ ID NO: 10 in the Sequence Listing is at least 5 times greater than the reactivity to VWF purified from human plasma (e) the Sequence Listing in which the antibody is immobilized on a microplate well Reacting with the peptide shown in SEQ ID NO: 10 in the sequence listing and the peptide shown in SEQ ID NO: 1 in the sequence listing, respectively, the reactivity against the peptide listed in SEQ ID NO: 10 in the sequence listing is shown in A property that is at least 3 times greater than the reactivity with respect to the peptide; (£) arrangement of the peptide and the sequence listing in SEQ ID NO: 10 in the sequence listing in which the antibody is immobilized on a microplate well; When reacted with the peptid
- the reactivity with respect to the peptide with SEQ ID No. 10 in the sequence listing is at least 5 times the reactivity with respect to the peptides with SEQ ID No. 8 and 11 in the sequence listing. It is preferable to have at least one of the characteristics of large heels and heels. These properties (a) to (l) can be confirmed using the methods of Examples 5 to 8 described later.
- the monoclonal antibody is prepared by a method commonly practiced in the art. That is, antibody-producing cells having specific affinity for an antigen (for example, N-10 peptide) are fused with myeloma cells to form a hyperidoma, and the hybridoma is cloned and specific for each protein. Produced by selecting clones that produce antibodies.
- an antigen for example, N-10 peptide
- an antigen for example, the ability to use the entire N-10 peptide As long as it contains at least tyrosine (Tyr) at the C-terminus and retains antigenicity, the N-10 peptide contains 1 to several amino acids. Changes such as deletion, substitution, or addition may be made.
- the antigen determining site is considered to have at least 4 amino acids, preferably 9 amino acids.
- a peptide having the amino acid sequence of SEQ ID NO: 10 in the sequence listing is used as the antigen.
- the amino acid sequence of the antigen peptide includes one or several amino acid deletions, substitutions, or additions. It ’s okay to make a change!
- the antigen can be prepared based on a selected partial amino acid sequence and / or synthesized or genetic engineering techniques.
- the peptide antigen obtained can be directly dissolved or suspended in an appropriate buffer such as phosphate buffer (PBS) as a sensitizing antigen.
- PBS phosphate buffer
- it is preferably used after being crosslinked with an appropriate carrier protein such as albumin or keyhole limpet hemocyanin.
- the antigen solution may be prepared usually at a concentration of about 50 to 500 gZml as the amount of the antigen substance.
- animals to be immunized with the antigen include mice, rats, horses, goats, and rabbits. Preferred are mice, more preferred are BALBZc mice.
- the antigen solution can be mixed with an adjuvant and administered.
- Adjuvants used in the present invention include Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA), Ribi (MPL), Ribi (TDM), Ribi (MPL + TDM), pertussis vaccine (Bordetella pertussisvaccine), Muramiruj Peptide (MDP), aluminum adjuvant (ALUM), and the power of which these combinations are exemplified Combinations that use FCA for the first immunization and FIA for the booster are particularly preferred.
- the injection site, schedule, and the like can be appropriately changed depending on the type of antigen used and the presence or absence of adjuvant mixing.
- adjuvant mixed antigen solution 0.05-: Lml (antigen substance 10-200 / ⁇ ) is injected intraperitoneally, subcutaneously, intramuscularly or (tail) intravenously, Perform booster immunization 1 to 4 times about every 4 to 14 days after immunization, and further about 1 to 4 weeks later.
- the antigen amount may be increased and injected intraperitoneally.
- the antibody titer is examined by collecting blood approximately 5-6 days after the boost. The antibody titer can be measured by a method commonly used in this field according to the antibody assay described below. About 3 to 5 days after the final immunization, the immunized animal splenocytes are separated to obtain antibody-producing cells.
- myeloma cells those derived from mice, rats, humans and the like are used.
- mouse Examples include Eroma P3X63-Ag8, P3X63-Ag8-Ul, P3NS1-Ag4, SP2Z0-Agl4, P3X63-Ag8, 653.
- Myeloma cells can be maintained by passage in conventional media supplemented with cryopreservation power, horse, rabbit, or fetal bovine serum.
- cells in the logarithmic growth phase are preferably used.
- Examples of methods for fusing antibody-producing cells and myeloma cells to form ibridomas include methods using polyethylene glycol (PEG), methods using Sendai virus, and methods using an electrofusion device. Is done.
- PEG polyethylene glycol
- splenocytes and myeloma cells are placed in an appropriate medium or buffer containing about 30 to 60% PEG (average molecular weight 1000 to 6000) 1 to LO: 1, preferably 5 to The suspension may be suspended at a mixing ratio of LO: 1 and allowed to react for about 30 seconds to 3 minutes under conditions of a temperature of about 25 to 37 ° C and a pH of 6 to 8. After the reaction is complete, remove the PEG solution, resuspend it in the medium, and inoculate it into a cellwell plate to continue the culture.
- PEG polyethylene glycol
- the cells after the fusion operation are cultured in a selective medium to select a hyperidoma.
- the selection medium is a medium in which the parent cell line can be killed and only the fused cells can grow.
- hypoxanthine-aminopterin-thymidine (HAT) medium is used.
- HAT hypoxanthine-aminopterin-thymidine
- the selection of hybridomas is started by exchanging a part of the medium, preferably about half of the medium, with the selective medium 1 to 7 days after the fusion operation, and the same medium exchange every 2 or 3 days. Repeat this step to incubate. The wells where colonies are growing are confirmed by microscopic observation.
- N-15 peptide the peptide of SEQ ID NO: 8 of the sequence listing (hereinafter also referred to as “N-15 peptide”) immobilized on the solid phase and measured in the same manner. Compare the signal of the N-10 peptide with the signal of the N-15 peptide and select the one with the former signal at least 10 times greater than the latter signal. Isolate single clones by Sarakuko, limiting dilution method, soft agar method, method using fluorescence excitation cell sorter.
- clones that produce the desired monoclonal antibody can be isolated by serially diluting and culturing the hyperpride macaque mouth--around 1 cell Zwell. .
- the resulting antibody-producing hybridoma is frozen in the presence of about 10% (vZv) dimethyl sulfoxide (DMSO) or a cryoprotectant such as glycerin.
- DMSO dimethyl sulfoxide
- ⁇ 1 When stored at 196 ° C, it can be stored for about half a year to semi-permanently. Cells should be used after rapid thawing in a constant temperature bath before and after use at 37 ° C. It is desirable that the cryoprotectant be thoroughly washed and used so that the cytotoxicity of the cryoprotectant does not remain.
- the monoclonal antibody of the present invention obtained by the above method is specifically a mouse-derived, IgG class or IgM class monoclonal antibody, for example, "VWF-peptide
- the hybridoma is cultured under general conditions, and the antibody class secreted in the culture supernatant is determined using a commercially available antibody class' subclass determination kit or the like. It can be examined by using and analyzing.
- the high-pridoma producing the monoclonal antibodies VWF-peptide Ab N10-116 and VWF-peptide Ab NIO-146 VWF-peptide Ab NIO-116 and VWF-
- the peptide Ab NIO-146 strain was newly isolated by the present inventors.
- the acquisition of the monoclonal antibody can be appropriately selected depending on the required amount, the properties of the hyperidoma, etc., from mouse ascites or by cell culture.
- Hypridoma that can grow in the peritoneal cavity of mice can be obtained from ascites at a high concentration of several mgZml. If you can't proliferate in vivo, Hypridoma can get the culture supernatant of cell culture. According to cell culture, antibody production is lower than in vivo, but there is an advantage that purification is easy because there is little contamination with immunoglobulins and other contaminants contained in the peritoneal cavity.
- a culture method such as a high-density culture method or a spinner flask culture method is used. And culture supernatant containing the antibody is obtained.
- Serum contains contaminants such as other antibodies and albumin, and there are many inconveniences in antibody purification, so it is desirable to reduce the amount of addition to the culture medium.
- Monoclonal antibodies with ascites and culture supernatant strength can be purified by a fractionation method by salting out using ammonium sulfate sodium sulfate, a polyethylene glycol fractionation method. It can be easily achieved by applying ethanol fractionation method, DEAE ion exchange chromatography method, gel filtration method, etc. Further, when the anti-monoclonal antibody of the present invention is a mouse IgG antibody, it can be purified by affinity chromatography using a protein A binding carrier or an anti-mouse immunoglobulin binding carrier. Convenient.
- ADAMTS 13 activity in a sample can be rapidly measured.
- VWF which is a natural substrate of ADAMTS 13
- a peptide consisting of 73 to 2050 amino acids preferably a peptide consisting of 73 to 210 amino acids, including the amino acid sequence represented by SEQ ID NO: 1 in the sequence listing, more preferably the amino acid of SEQ ID NO: 1.
- a peptide consisting of a sequence (VWF73) can be used as a substrate.
- Such a substrate is preferably expressed and prepared using a genetic engineering technique with, for example, a dartathione-S-transferase (GST) tag attached to the N-terminus of the substrate molecule (hereinafter also referred to as “GST-VWF73 substrate”).
- GST dartathione-S-transferase
- an enzyme labeled at the N-terminus of VWF73 for example, a VWF73 substrate labeled at the N-terminus with horse radish peroxidase (HRP) can be used.
- HRP-labeled VWF73 substrate add several amino acids to the N-terminus of the VWF73 peptide, and mutate one amino acid to cysteine.
- VWF73 prepared for use as these substrates can be summarized as follows: HRP labeling via Cys (J. Thromb. Haemo st., 4, 129-136, 2006) Sometimes referred to as “VWF73 substrate”.
- the substrate is allowed to react with the sample to be measured for ADAMTS13 activity for a certain period of time, and the fraction containing the product (for example, N-10 peptide when using VWF73 substrate) in the enzyme-substrate reaction mixture is measured.
- the measuring method is not limited as long as the antibody of the present invention is used.
- various types of immunoassays usually performed in the art can be used.
- the method is not particularly limited as long as it includes a step of reacting the enzyme substrate reaction mixture with the antibody of the present invention and measuring the formed immune complex, and optically detects a precipitation reaction or an agglutination reaction.
- An immunoturbidimetric assay method, or an antibody labeled with a substance that can be easily detected separately, or a labeled immunoassay method can be used.
- Labeled immunoassays include radioimmunoassay using RI as a label for detection of immune complexes, enzyme immunoassay using enzymes such as alkaline phosphatase peroxidase, and fluorescent immunoassay using fluorescent substances. Is included.
- a direct method of directly labeling the antibody to be detected an indirect method of labeling the antibody of the antibody to be detected, that is, the secondary antibody, or the like can be used.
- the indirect method for example, when the antibody of the present invention is a mouse IgG monoclonal antibody, for example, an anti-mouse IgG polyclonal antibody or the like is used as the secondary antibody.
- the method for preparing the secondary antibody and the labeling of the antibody with a fluorescent substance, RI, enzyme, etc. can be carried out using methods commonly used in this field.
- a method using a reaction of piotin-avidin (or streptavidin) is also possible for the measurement method, and it is preferably employed in the case of measurement requiring high sensitivity.
- Examples of the method include a method using a combination of the antibody of the present invention labeled with piotin and streptavidin labeled with a fluorescent substance.
- the antibody of the present invention can be labeled with piotin and streptavidin with a fluorescent substance or the like using a method commonly used in the art.
- streptavidin labeled with a fluorescent substance or the like is commercially available. It is available.
- a polyclonal antibody can be prepared as follows. Use the same antigen as the monoclonal antibody to animals such as rabbits, goats, hidges, rats, and mice. Immunize and get antisera. Since generally obtained antisera contain antibodies that cause non-specific reactions, it is possible to perform specific absorption by performing absorption procedures with substances that can cause non-specific reactions such as human serum, human VWF, and VWF73. Raise sex. It is also possible to obtain antibodies with high specificity that meet the purpose of the present invention by affinity purification with the immunogen used. The obtained antibody can be used for the measurement of ADAMTS13 activity as in the case of the monoclonal antibody.
- an antibody of the present invention a monoclonal antibody (hereinafter, also referred to as “anti-N-10 monoclonal antibody”) obtained using N-10 peptide as an immunogen, and the aforementioned GST-VWF73 substrate as a substrate are used.
- the ability to disclose a method for measuring ADAMTS13 activity is sufficient if the antibody is an antibody of the present invention.
- the substrate is not particularly limited as long as it is a peptide that can be hydrolyzed to ADAMTS13.
- An anti-GST antibody is immobilized on a solid phase carrier such as a microtiter plate, tube or magnetic particle, and a GST-VWF73 substrate is immobilized on the solid phase in advance. After reacting the solid phase with the reaction buffer and the sample, react with anti-N-10 monoclonal antibody, and measure the amount of anti-N-10 monoclonal antibody on the solid phase to measure ADAMTS13 activity in the sample. It is possible. It is preferable to label the anti-N-10 monoclonal antibody with a known labeling substance.
- An anti-GST antibody is immobilized on a solid phase carrier such as a microtiter plate, tube or magnetic particle, and a GST-VWF73 substrate is immobilized on the solid phase in advance.
- the ADAMTS 13 activity in the sample is measured by reacting the solid phase with the reaction buffer, the sample, and the anti-N-10 monoclonal antibody simultaneously, and measuring the amount of the anti-N-10 monoclonal antibody on the solid phase. It is possible. It is preferable to label the anti-N-10 monoclonal antibody with a known labeling substance.
- anti-N -It After reacting the GST-VWF73 substrate, reaction buffer and specimen with an anti-GST solid phase in which anti-GST antibody is immobilized on a solid phase carrier such as a microtiter plate, tube or magnetic particle, anti-N -It is possible to measure ADAMTS13 activity in a sample by reacting with 10 monoclonal antibody and measuring the amount of anti-N-10 monoclonal antibody on the solid phase It is. It is preferable to label the anti-N-10 monoclonal antibody with a known labeling substance.
- GST-VWF73 substrate, reaction buffer, specimen and anti-N-10 monoclonal antibody are simultaneously applied to an anti-GST solid phase in which anti-GST antibody is immobilized on a solid phase carrier such as a microtiter plate, tube or magnetic particle. It is possible to measure ADAMTS13 activity in a sample by reacting and measuring the amount of anti-monoclonal antibody on the solid phase. It is preferable to label the anti-N-10 monoclonal antibody with a known labeling substance.
- the reaction mixture is immobilized in advance on a solid phase carrier such as a microtiter plate, tube or magnetic particles. It is possible to measure ADAMTS13 activity by reacting with anti-GST antibody and then reacting with anti-N-10 monoclonal antibody and measuring the amount of anti-N-10 monoclonal antibody bound on the solid phase. . It is preferable to label the anti-N-10 monoclonal antibody with a known labeling substance.
- reaction mixture After reacting the GST-VWF73 substrate, reaction buffer, sample, and anti-N-10 monoclonal antibody in a test tube or other container, the reaction mixture is mixed with a microtiter plate, tube, magnetic particle, etc. It is possible to measure ADAMTS 13 activity by reacting with an anti-GST antibody previously immobilized on a solid phase carrier and measuring the amount of anti-N-10 monoclonal antibody bound on the solid phase. It is preferable to label the anti-N-10 monoclonal antibody with a known labeling substance.
- the reaction mixture is immobilized in advance on a solid phase carrier such as a microtiter plate, tube or magnetic particles. It is possible to measure ADAMTS 13 activity by reacting with the anti-N-10 monoclonal antibody and then reacting with the anti-GST antibody and measuring the amount of the anti-GST antibody bound on the solid phase. It is preferable to label the anti-GST antibody with a known labeling substance.
- reaction mixture After reacting the GST-VWF73 substrate, reaction buffer, sample, and anti-GST antibody in a test tube or other container, the reaction mixture is mixed with a solid phase carrier such as a microtiter plate, tube, or magnetic particle. React with anti-N-10 monoclonal antibody previously immobilized on It is possible to measure ADAMTS 13 activity by measuring the amount of anti-GST antibody bound above. It is preferable to label the anti-GST antibody with a known labeling substance.
- a solid phase carrier such as a microtiter plate, tube, or magnetic particle.
- ADAMTS13 activity can be measured by reacting anti-GST antibody and then measuring the amount of anti-GST antibody bound on the solid phase. It is preferable to label the anti-GST antibody with a known labeling substance. It is also possible to react the anti-GST antibody with the GST-VWF73 substrate in advance, as an example of this measurement method.
- Anti-GST antibody is immobilized on microscopically or physically detectable fine particles such as colloidal gold particles or colored latex particles, then reacted with GST-VWF73 substrate, and then a reaction buffer and specimen are added. In addition, an enzyme reaction is performed. After that, the reaction solution is guided to a porous carrier such as filter paper or membrane on which anti-N-10 monoclonal antibody is fixed, and particles such as gold colloid particles or colored latex particles captured on the porous carrier are detected. It is possible to measure ADA MTS 13 activity.
- a known lateral flow method or flow-through method is suitably selected as a method for introducing the reaction solution to a porous carrier such as filter paper or membrane on which an anti-N-10 monoclonal antibody is immobilized.
- a known reaction vessel suitable for optical detection of evanescent waves as a solid phase carrier and operate in the same manner as in 4 above to label the anti-N-10 monoclonal antibody labeled with a fluorophore suitable for evanescent wave detection.
- ADAMTS 13 activity When used, it is possible to measure ADAMTS 13 activity by evanescent wave detection. Furthermore, in this case, the intensity of the evanescent wave is measured over time. Thus, it is also possible to rate-act AD AMTS 13 enzyme activity. Using this method, hosiery assembly is possible without the need for washing or BZF separation.
- ADAMTS 13 Immobilize the anti-GST antibody on gold colloidal particles or latex particles, react with GST-VWF73 substrate, and add the reaction buffer and sample to perform the enzyme reaction. Then, ADAMTS 13 activity can be measured by adding anti-N-10 monoclonal antibody to the reaction solution, inducing agglutination of particles and detecting the aggregation optically or macroscopically. is there.
- an anti-GST antibody preferably an anti-GST monoclonal antibody, is added to the reaction mixture to induce particle agglutination, and the aggregation is detected optically or macroscopically. The activity can be measured.
- reaction solution After reacting a specimen using human or animal VWF as a substrate, the reaction solution can be separated by gel electrophoresis and reacted with the antibody of the present invention to measure ADAMTS13 activity.
- Anti-VWF antibody is immobilized on a solid phase carrier such as a microtiter plate, tube or magnetic particle, and VWF is immobilized on the solid phase in advance. After reacting the solid phase with the reaction buffer and the sample, anti-N-10 monoclonal antibody is reacted, and the amount of anti-monoclonal antibody on the solid phase is measured to measure ADAMTS13 activity in the sample. It is possible.
- the following method can be mentioned as a further specific example of the method for measuring ADAMTS13 activity using the antibody of the present invention.
- the anti-N-10 monoclonal antibody is used as the antibody of the present invention, and the substrate is not limited to these, using the VWF73 substrate labeled at the N-terminus with HRP as described above.
- the reaction mixture is immobilized in advance on a solid phase carrier such as a microtiter plate, tube, or magnetic particle.
- a solid phase carrier such as a microtiter plate, tube, or magnetic particle.
- ADAMTS 13 activity can be measured.
- 2.HRP-labeled VW F73 substrate, reaction buffer, anti-N-10 monoclonal antibody solid phase obtained by immobilizing anti-N-10 monoclonal antibody on solid phase carrier such as microtiter plate, tube or magnetic particle
- the ADAMTS 13 activity can be measured by reacting the sample and the sample at the same time, measuring the HRP activity on the solid phase after washing.
- an anti-His tag antibody is used instead of the above anti-GST antibody in the same manner. Can be implemented.
- the above method can be carried out by using a conjugate that can specifically bind to each tag.
- the sample measured by the measurement method of the present invention is generally blood with no particular restriction.
- the measurement can be performed at the cell and tissue force extract, etc. It is also possible to measure using the above sample as a specimen. These measurement methods can be applied to methods usually performed in the field.
- the novel antibody of the present invention can be included in a reagent or a kit.
- the reagent or kit herein include a reagent or kit for measuring ADAMTS13 activity in a sample, and a clinical examination reagent or kit.
- the antibody used here refers to both a monoclonal antibody and a polyclonal antibody, and is not limited as long as the object of the present invention can be achieved.
- the antibody of the present invention is also applied to a clinical test by measuring ADAMTS13 activity, and the present invention extends to the test method.
- Applicable clinical tests include thrombotic thrombocytopenic purpura (TT P), hemolytic uremic syndrome (HUS), disseminated intravascular coagulation syndrome (DIC), cerebral infarction, chronic liver disease, malignant tumor, HIV, myocardial infarction It can be applied to the examination of risk factors for disease progression of microvascular disorders such as autoimmune diseases, pregnancy complications, and acute renal failure.
- the present invention extends to a reagent or kit for measuring ADAMTS 13 activity and the above-described test reagent or kit.
- These reagents or kits contain the antibody of the present invention, and optionally contain VWF or peptide that can serve as a substrate.
- Reagent or kit contains ADAMTS 13 substrate and N-10 peptide, which is a hydrolysis product of the substrate.
- a fraction suitable for immunoassay using the anti-N-10 monoclonal antibody of the present invention can be appropriately selected and included.
- kits by appropriately combining solid phase reagents such as microplates on which antibodies are immobilized and magnetic particles, labeled antibody reagents, enzyme substrate reagents, standard solutions, washing solutions, and the like.
- the present invention includes, for example, an anti-N-10 monoclonal antibody using N-10 peptide (a peptide having an N-terminal site generated by cleavage of VWF or VWF73), and ADAMTS13 activity using the same.
- Antibodies against are also included. More specifically, it is an antibody against the peptide shown in SEQ ID NO: 10 in the sequence listing, or an antibody against the peptide containing the sequence shown in SEQ ID NO: 12 in the sequence listing on the N-terminal side.
- Antibodies that do not substantially react with VWF73, methods for measuring ADAMTS13 activity using these antibodies, and reagents or kits containing these antibodies are also included.
- mice 7-8 weeks old inbred BALBZc mice females are bred using standard pellets in an animal breeding chamber (23 ⁇ 1 ° C, humidity 70%) and optionally supplied with water. And reared.
- Immune antigen A chemically synthesized N-10 peptide represented by SEQ ID NO: 2 in the sequence listing was used as an N-10 peptide antigen.
- mice with high antibody titers were further immunized two weeks later by injecting N-10 peptide antigen prepared in PBS to 100 gZ ml from the tail vein of mice.
- the antibody titer was measured using the serum of a mouse immunized with the antigen according to the screening method described below.
- X63 cells are subcultured in DMEM culture medium (containing 5 ⁇ g / m 1 6-thioguanine) containing 10% fetal calf serum (FCS) and contain 6-thioguanine 3 days before cell fusion. Not further cultured in DMEM culture medium containing 10% FCS, and cells in logarithmic growth phase were used. The number of X63 cells was counted and 1.9 ⁇ 10 8 viable cells were obtained. Dissolve polyethylene glycol-1500 to a concentration of 50 (wZv)% in DMEM culture medium, mix the mixture so that the ratio of the above spleen cells to X63 cells is 1: 1, and use a known method (Keller And Milstein, Nature, 256, 495-497, 1975, Eur.
- FCS fetal calf serum
- the plate was washed 5 times with an acid buffer solution (hereinafter abbreviated as a washing solution), and further blocked with a phosphate buffer solution containing 10% Block Ace (trade name) to prepare an N-10 peptide-immobilized plate.
- the culture supernatant 100 1 obtained above is added to the immobilized plate, reacted at 37 ° C for 60 minutes, washed 5 times with a washing solution, and further horseradish perovskite.
- HRP Xidase
- a labeled anti-mouse immunoglobulin antibody (derived from goat) was reacted at 37 ° C for 60 minutes.
- the plate was washed 4 times with a washing solution, and the substrate solution (containing 0-phenoldiamine 0.4 mgZml and 0.02% HO) was reacted at 37 ° C for 15 minutes, and then this reaction was treated with 2N sulfuric acid. Stop at the main
- a labeled anti-mouse immunoglobulin antibody (derived from goat) was reacted at 37 ° C for 60 minutes. After this reaction, the plate was washed 4 times with the washing solution, and the substrate solution (0-phenoldiamine 0.4 mg Zml and 0.02% HO) was obtained. Reaction) at 37 ° C for 15 minutes, and then the reaction was stopped with 2N sulfuric acid,
- the monoclonal antibody of the present invention was found to be an antibody that specifically recognizes the vicinity of the C-terminus of the N-10 peptide.
- mouse immunoglobulin subclass was determined for the monoclonal antibody produced by the hyperidoma cell line obtained as a single clone by the above cloning. To identify the mouse immunoglobulin subclass, the culture supernatant of each hybridoma cell line was used, and the mouse monoclonal antibody isotyping kit manufactured by Serotec was used. As a result, clones VWF-peptide Ab Nl 0-116 and VWF-peptide Ab N10-146 were both found to be IgG2.
- ADAMTS13 is a metalloenzyme, and a divalent metal is required for the expression of activity, so 5 mM Tris containing 20 mM barium chloride.
- N10-146 an anti-N-10 monoclonal antibody
- anti-mouse immunoglobulin antibody labeled with horse radish peroxidase HRP
- HRP horse radish peroxidase
- clone N 15Ab undergoes an enzymatic reaction with ADAMTS 13!
- the absorbance in the reaction solution containing barium chloride is almost equal to the absorbance in the reaction solution containing EDTA.
- the N-10 peptide produced by the enzyme reaction with ADAMTS13 is the same as the VWF73 substrate. It proved to be impossible to measure separately.
- the anti-N-10 monoclonal antibody (N10-146) of the present invention the enzyme reaction with ADAMTS 13 proceeds!
- the anti-N-10 monoclonal antibody of the present invention has extremely low reactivity with the VWF73 substrate, and the N-10 peptide generated by enzymatic hydrolysis of the substrate by AD AMTS13 has a very high specificity. It was found to react with Therefore, it has been clarified that ADAMTS 13 activity can be measured by using the anti-N-10 monoclonal antibody of the present invention.
- Example 5 Each of the seven types of peptides shown in SEQ ID NO: 2 in the Sequence Listing (each N-10 peptide, N-6 peptide, N-8 peptide, N-11 peptide, N-9 peptide, N-13 peptide, N- 15 peptides) at a concentration of 1 ⁇ gZml was dispensed 100 ⁇ l at a time on microtiter plate wells, left overnight at 28 ° C., washed and blocked to prepare each peptide solid phase.
- Each peptide solid phase was reacted with peroxidase (HRP) -labeled anti-N-10 monoclonal antibody (N 10-146) derived from horse radish to examine the reactivity of the anti-N 10 -monoclonal antibody with each peptide.
- HRP peroxidase
- the N-10 monoclonal antibody was reactive only with the N-10 peptide and not significantly reactive with any of the other peptides. Therefore, it was found that the N-10 monoclonal antibody of the present invention is specific for the N-10 peptide, and the force is also specific for the region containing the C-terminal tyrosine of the N-10 peptide.
- each peptide was preliminarily added to the HRP-labeled anti-N-10 monoclonal antibody (N10-14 6) at a concentration of 15. 6 31. 3 62. 5 125 2 50 500 lOOOngZml. After the reaction, it was reacted with an N-10 peptide solid phase.
- the anti-N10-monoclonal antibody of the present invention is specific to the N-10 peptide and also specific to the region containing the tyrosin at the C-terminal of the N-10 peptide.
- Samples obtained by diluting normal human plasma with human plasma (heated plasma) heat-treated at 56 ° C for 30 minutes XI, X 2, X 4, X 8, X 16, X 32, X 64 times and heated plasma were used as samples.
- the other procedures were carried out in the same manner as in Example 4, and a calibration curve for measuring ADAMTS 13 activity was prepared using XI in normal human plasma as 100% ADAMTS13 activity.
- X-axis shows ADAMTS 13 activity (%)
- Y-axis shows absorbance at 492 nm.
- No. 116 shows the result of measurement using anti-N-10 monoclonal antibody N10-116. The absorbance was confirmed to increase in proportion to ADAMTS 13 activity, and it was found that ADAMTS13 activity can be measured by the method of the present invention.
- a calibration curve of ADAMTS 13 activity was prepared in the same manner as in Example 4, and simultaneously ADAMTS 13 activity in plasma of congenital ADAMTS 13 deficiency (USS case) was measured.
- ADAMTS13 activity in USS cases was calculated to be 1% or less (arrow in FIG. 1). This result was in good agreement with the VWF multimer analysis. Therefore, it was found that the ADMTS 13 activity can be specifically measured by the method of the present invention, and it was revealed that it is useful for clinical examination.
- Anti-N-10 monoclonal antibody (N 10-146) of the present invention was dispensed at 100 g 1 at a concentration of 1 gZml to each well of the microtiter plate and allowed to stand overnight to prepare an anti-N-10 antibody solid phase. .
- a test tube take 100 1 of VWF73 substrate (1 / z gZml) and 10 1 test plasma (prepared by diluting normal human plasma with heated plasma as in Example 7) at 37 ° C for 1 hour. After the reaction, 20 ⁇ l of 50 mM EDTA was added to stop the reaction.
- reaction product 100 ⁇ l of the reaction product was reacted with the anti- ⁇ -10 antibody solid phase at room temperature for 1 hour, washed, and then washed with HRP-labeled anti-GST antibody (derived from goat). Reacted for 1 hour. The absorbance generated by the enzyme reaction was measured. XI of normal human plasma was taken as 100% test plasma concentration (ADAMTS13 activity).
- FIG. X-axis shows test plasma concentration (ADAMTS13 activity) (%)
- Y-axis shows absorbance at 492 nm.
- ADAMTS13 activity can be measured and tested, and can be used for the development of therapeutic agents, diagnostic agents, etc. based on the results.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES06712413T ES2382487T3 (es) | 2005-02-14 | 2006-01-26 | Anticuerpo para el análisis de la actividad de la ADAMTS13 y método de análisis de la actividad |
EP06712413A EP1852442B1 (en) | 2005-02-14 | 2006-01-26 | Antibody for assay of adamts13 activity and method of activity assay |
US11/816,168 US7833726B2 (en) | 2005-02-14 | 2006-01-26 | Antibody for assaying ADAMTS13 activity and method for assaying the activity |
AU2006213411A AU2006213411B2 (en) | 2005-02-14 | 2006-01-26 | Antibody for assay of ADAMTS13 activity and method of activity assay |
CA2597545A CA2597545C (en) | 2005-02-14 | 2006-01-26 | Antibody for assay of adamts13 activity and method for assaying the activity |
JP2007502561A JP4913034B2 (ja) | 2005-02-14 | 2006-01-26 | Adamts13活性検定用抗体及び活性検定方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005036612 | 2005-02-14 | ||
JP2005-036612 | 2005-02-14 | ||
JP2005-157530 | 2005-05-30 | ||
JP2005157530 | 2005-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006085441A1 true WO2006085441A1 (ja) | 2006-08-17 |
Family
ID=36793019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/301231 WO2006085441A1 (ja) | 2005-02-14 | 2006-01-26 | Adamts13活性検定用抗体及び活性検定方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7833726B2 (ja) |
EP (1) | EP1852442B1 (ja) |
JP (2) | JP4913034B2 (ja) |
AU (1) | AU2006213411B2 (ja) |
CA (1) | CA2597545C (ja) |
ES (1) | ES2382487T3 (ja) |
WO (1) | WO2006085441A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1889919A1 (en) * | 2005-05-20 | 2008-02-20 | Mitsubishi Kagaku Iatron, Inc. | Method of analyzing enzyme |
JP2012510817A (ja) * | 2008-12-05 | 2012-05-17 | バクスター・インターナショナル・インコーポレイテッド | フォンビルブランド因子のadamts13媒介インビボ切断を測定する方法およびその使用 |
JP2019532649A (ja) * | 2016-10-11 | 2019-11-14 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Adamts13酵素活性を決定するための方法およびシステム |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2918375B1 (fr) * | 2007-07-05 | 2009-10-16 | Lab Francais Du Fractionnement | Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma |
EP3548899B1 (en) * | 2016-11-30 | 2023-10-18 | BERBI Biomedizinische Forschung, Entwicklung und Beratung Gesellschaft m.b.H. | Rapid semiquantitative method for determining adamts-13 activity in a patient plasma sample |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035778A1 (ja) * | 2002-10-18 | 2004-04-29 | Japan As Represented By The President Of National Cardiovascular Center | フォンビルブランド因子切断酵素の特異的基質および活性測定法 |
WO2005008241A1 (en) | 2003-07-07 | 2005-01-27 | University Of North Carolina At Chapel Hill | Method and system for detection of von willebrand factor (vwf) multimers |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2007A (en) * | 1841-03-16 | Improvement in the mode of harvesting grain | ||
US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
JP2003284570A (ja) * | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子(vWF)切断酵素 |
CN101412759A (zh) * | 2003-01-10 | 2009-04-22 | 埃博灵克斯股份有限公司 | 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用 |
US20050186646A1 (en) * | 2004-01-26 | 2005-08-25 | Cruz Miguel A. | Rapid assay to detect ADAMTS-13 activity |
-
2006
- 2006-01-26 EP EP06712413A patent/EP1852442B1/en active Active
- 2006-01-26 AU AU2006213411A patent/AU2006213411B2/en active Active
- 2006-01-26 ES ES06712413T patent/ES2382487T3/es active Active
- 2006-01-26 WO PCT/JP2006/301231 patent/WO2006085441A1/ja active Application Filing
- 2006-01-26 JP JP2007502561A patent/JP4913034B2/ja active Active
- 2006-01-26 US US11/816,168 patent/US7833726B2/en active Active
- 2006-01-26 CA CA2597545A patent/CA2597545C/en active Active
-
2011
- 2011-12-02 JP JP2011264811A patent/JP2012082210A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035778A1 (ja) * | 2002-10-18 | 2004-04-29 | Japan As Represented By The President Of National Cardiovascular Center | フォンビルブランド因子切断酵素の特異的基質および活性測定法 |
WO2005008241A1 (en) | 2003-07-07 | 2005-01-27 | University Of North Carolina At Chapel Hill | Method and system for detection of von willebrand factor (vwf) multimers |
Non-Patent Citations (2)
Title |
---|
OOUMI S.: "Cell technology Separate Volume Jikken Protocol Series New Edition Anti-peptide Kotai Jikken Protocol - Idenshi Sanbutsu no Dotei kara Tanpakushitsu Kino Kaiseki made -", SHUJUNSHA CO., LTD., 2004, pages 130 - 143, XP003000547 * |
See also references of EP1852442A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1889919A1 (en) * | 2005-05-20 | 2008-02-20 | Mitsubishi Kagaku Iatron, Inc. | Method of analyzing enzyme |
EP1889919A4 (en) * | 2005-05-20 | 2009-04-15 | Mitsubishi Kagaku Iatron Inc | METHOD FOR ANALYZING AN ENZYME |
JP2012510817A (ja) * | 2008-12-05 | 2012-05-17 | バクスター・インターナショナル・インコーポレイテッド | フォンビルブランド因子のadamts13媒介インビボ切断を測定する方法およびその使用 |
JP2015213513A (ja) * | 2008-12-05 | 2015-12-03 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | フォンビルブランド因子のadamts13媒介インビボ切断を測定する方法およびその使用 |
JP2017153490A (ja) * | 2008-12-05 | 2017-09-07 | バクスアルタ インコーポレイテッド | フォンビルブランド因子のadamts13媒介インビボ切断を測定する方法およびその使用 |
JP2020022515A (ja) * | 2008-12-05 | 2020-02-13 | バクスアルタ インコーポレイテッド | フォンビルブランド因子のadamts13媒介インビボ切断を測定する方法およびその使用 |
JP2019532649A (ja) * | 2016-10-11 | 2019-11-14 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Adamts13酵素活性を決定するための方法およびシステム |
US11959124B2 (en) | 2016-10-11 | 2024-04-16 | Laboratory Corporation Of America Holdings | Methods and systems for determining ADAMTS13 enzyme activity |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006085441A1 (ja) | 2008-06-26 |
EP1852442A4 (en) | 2008-12-03 |
JP2012082210A (ja) | 2012-04-26 |
US20090142776A1 (en) | 2009-06-04 |
CA2597545A1 (en) | 2006-08-17 |
US7833726B2 (en) | 2010-11-16 |
EP1852442A1 (en) | 2007-11-07 |
AU2006213411B2 (en) | 2010-09-23 |
CA2597545C (en) | 2012-02-14 |
AU2006213411A1 (en) | 2006-08-17 |
JP4913034B2 (ja) | 2012-04-11 |
ES2382487T3 (es) | 2012-06-08 |
EP1852442B1 (en) | 2012-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103408663B (zh) | 抗人cxcl1单克隆抗体或其片段 | |
WO1994004563A1 (en) | PEPTIDES CONTAINING RESPECTIVE AMINO ACID SEQUENCES SELECTED FROM AMONG THOSE OF LIPOPROTEIN(a) AND APOLIPOPROTEIN(a), ANTIBODIES RESPECTIVELY RECOGNIZING THESE AMINO ACID SEQUENCES, AND METHOD OF ASSAYING WITH THESE ANTIBODIES | |
JP2012082210A (ja) | Adamts13活性検定用抗体及び活性検定方法 | |
KR102100152B1 (ko) | Pivka-ⅱ 측정 방법, 측정 시약 및 측정 키트 | |
US20200166512A1 (en) | Composition and methods for detecting cancer | |
JPH0648994B2 (ja) | ヒトの心房ナトリウム排泄増加性ペプチドに対するモノクローナル抗体 | |
JPH10226700A (ja) | Miaの検出のためのイムノアッセイ | |
JP4533995B2 (ja) | 抗adamts13モノクローナル抗体 | |
JP3888695B2 (ja) | ヒトlect2に対する抗体、それを産生する細胞、その測定法及び測定用キット | |
US20190369095A1 (en) | Novel antibody for determination of adamts-13 activity | |
JP2518602B2 (ja) | ヒトプロテインsに対するモノクロ―ナル抗体を用いた免疫学的測定試薬及びキット | |
US8349569B2 (en) | Anti-fibronectin fragment monoclonal antibody | |
JP4838436B2 (ja) | 抗ヒト肝性トリグリセリドリパーゼ抗体 | |
JP2022142169A (ja) | パラチロイドホルモンの測定方法 | |
JPH0772148A (ja) | ヒトiv型コラーゲンのサンドイッチ酵素免疫学的定量用試薬 | |
JP2003180345A (ja) | 遊離型肝細胞増殖因子受容体の測定方法 | |
JP2005314397A (ja) | 抗コンドロモジュリン−1特異的抗体及びその利用 | |
JP2011251969A (ja) | 抗ヒト肝性トリグリセリドリパーゼ抗体 | |
JPH03206882A (ja) | 抗hCG―βコアモノクローナル抗体産生ハイブリドーマ、該モノクローナル抗体およびその用途 | |
CN102597772A (zh) | 5.9kDa肽的免疫学测定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007502561 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11816168 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2597545 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006213411 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006712413 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006213411 Country of ref document: AU Date of ref document: 20060126 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006213411 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006712413 Country of ref document: EP |